International Board MATWIN
MATWIN International Board is a strategic committee of the MATWIN programme.
It gathers academic leaders in oncology coming from all over Europe and international industrial leaders from the global oncology R&D department of MATWIN’s industrial partners. They interview project leaders, provide recommendations and label those with the highest industrial development transfer potential.
Since 2017, MATWIN also invites representatives of major venture capital firms (Sofinnova Partners, Kurma Partners) to join the Board meeting. Those representatives can therefore benefit from a unique expertise feedback to detect projects with potential interest and support financially their development.
MATWIN International Board quality reflects the level of involvement of all partners, and specifically industrial partners. This committee is today quite unique in Europe within research and innovation environment. The Board members meet once a year to try and take up the maturation challenge in oncology. As part of the call for proposals that MATWIN launches every year, the International Board members meet for 2 days each year in May to interview the best projects selected through the MATWIN process.
BOARD ACADEMIC MEMBERS
Jean-Pierre BIZZARI, M.D., served as Executive Vice-President, Group Head, and Clinical Oncology Development (U.S., Europe, and Asia/Japan) at Celgene from 2008 to 2015. As a world-renowned oncology expert, he is a member of the Scientific Advisory Board of the French National Cancer Institute (INCa) and European Organization of Research and Treatment of Cancer (EORTC) and Chairman of the New Drug Advisory Committee. Mr. Bizzari is also an active board member in various biotech companies.
Bizzari joined the pharmaceutical industry in 1983 as Head of Oncology at the Institut de Recherches Internationales SERVIER (France). He then joined Rhône-Poulenc Rorer in 1993 as Vice President of Clinical Oncology, based in Paris and moved to Collegeville (PA – USA) in 1997. From 2002 until 2008, Mr. Bizzari served as Vice President of Clinical Oncology Development at Sanofi-Aventis in Malvern, PA before joining Celgene.
Jean-Pierre Bizzari holds a medical degree specialized in oncology from the University of Nice (France) and has trained successively at the Pitié-Salpêtrière hospital in Paris, at Ontario Cancer Institute, and Montreal Mac Gill Cancer Center in Canada.
Olivier HERMINE is Professeur at Paris Descartes University (France), hospital practitioner and has the scientific degree of doctor.
He is responsible of a research group studying mechanisms of hematologic malignancy or “blood cancer”. He is also the mastocytoses reference centre coordinator (CeReMast). He has received in 2011 the medical research foundation price from the “Collège de France” and in 2008 the Jean-Bernard price at the French medical Victory.
Michel MARTY is Head of the Therapeutics innovation in oncology centre and haematologist at the Saint-Louis University hospital in Paris (France). Medical Doctor at the Paris VI university in 1975, he is Professor in oncology at the Paris VII University. Member of several International learned societies, he has published more than 450 publications. He is actively involved in new cancer treatments studies. He is head of the oncology and haematology working group at the French national drug agency and at the European medicine agency (EMA). He is also Head of the annual Eurocancer congress.
Paul MOSS is Director of Research and Knowledge Transfer at the University of Birmingham and Chairman of the Infection and Immunity Board at the Medical Research Council. He served previously as Chair of the Cancer Research UK Clinical and Translational Research Committee. He is a Clinical Haematologist with a large laboratory programme investigating immune mechanisms in cancer, transplantation and viral infection. He is the chief investigator of several clinical trials and contributes to a number of Biotech advisory Boards.
Peter PARKER is Head of the Cancer Division at King’s College London and Senior Group Leader at the Francis Crick Institute. Professor Peter Parker has run a cancer research group since 1986 publishing over 300 primary research articles and reviews in the area of signal transduction, cancer molecular biology and drug development.
Miguel A PIRIS is pathologist, author of more than 270 articles in lymphoma diagnosis and cancer molecular pathogenesis. He is currently the Chief of Service at the Pathology Department in the Hospital Universitario Marques de Valdecilla, Santander, Spain and Scientific Director at the Research Institute IFIMAV. Former director of the Molecular Pathology Program at the Spanish National Cancer Centre (CNIO) for 12 years and member of the Leopoldina Academy, he is currently the President of the Spanish Society of Pathology.
Pedro ROMERO obtained his MD at the School of Medicine of the National University of Colombia in Bogota. Then he performed experimental work in the field of immunology of malaria and participated in the development of malaria vaccines, initially at the Institute of Immunology, Faculty of Medicine, National University of Colombia in Bogota and then as a postdoctoral fellow at the Department of Medical and Molecular Parasitology, New York University School of Medicine. He joined the Lausanne branch of the Ludwig Institute for Cancer Research in 1989. He is currently a Member of the Ludwig Center for Cancer Research, is the head of the Translational Tumor Immunology Group at the Ludwig Center and Director of the Division of Fundamental Oncology at the Lausanne University Hospital. He was named Ordinary Professor at the Faculty of Biology and Medicine January 2011. He has been actively involved in pre-clinical and translational research in tumor immunology and immunotherapy. His main interests focus on the study of tumor antigens, human T cell responses and development of immunotherapy of cancer. Dr. Romero has co-authored over 250 publications in peer-reviewed journals and serves as editor in various biomedical journals, including Editor-in-Chief of the Journal for Immunotherapy of Cancer.
BOARD INDUSTRIAL MEMBERS
Dr David Andrews trained as a pharmacist at Nottingham University and then undertook PhD research in organic synthesis at Liverpool University. From 1990-2003, he held positions of increasing seniority in medicinal chemistry at GlaxoSmithKline. In 2003, he joined the Oncology iMed Chemistry Department of AstraZeneca where he led projects delivering the development candidates AZD4547, AZD9496 and AZD0364. Scientifically, David’s current main interests lie in Oncology, with around 60 publications and patents that span cancer and infection medicinal chemistry as well as synthetic chemistry and Open Innovation. He is currently Director of Pre-clinical Scientific Alliances, accountable for a large portfolio of Discovery-phase project collaborations across Asia, EU and North America.
Jay T. BACKSTROM, MD, MPH, Senior Vice President, is responsible for Global Regulatory Affairs and for the late stage clinical programs across the Hematology Oncology portfolio at Celgene. Prior to assuming this position in May 2014, Dr Backstrom served as Senior Vice President, Global Regulatory Affairs and Pharmcovigilance a position he assumed in September 2012 after spending 2 years as Corporate Vice President, Hematology Clinical R&D. Dr Backstrom joined Celgene in March 2008 as Vice President, Clinical R&D after serving as Vice President, Global Medical Affairs and Safety at Pharmion. Dr Backstrom has 24 years in drug development with the last 12 years focused in Hematology/Oncology. Prior to joining Pharmion in 2002, Dr Backstrom was with Marion Merrell Dow and its successor companies including Hoechst Marion Roussel where he held positions in Clinical Research and Global Drug Surveillance and Pharmacoepidemiology.
Arthur BERTELSEN joined Bristol-Myers Squibb Research in April of 2010 as Vice President Research Collaborations. In this role, Art has overall responsibility for the management of external research collaborations.
Prior to joining BMS Art spent more than twelve years at Schering-Plough Research Institute where he was responsible for all aspects involving the formation and management of external research collaborations to discover therapeutics and integrate new technology into discovery operations. Among other accomplishments at Schering-Plough Art conceived and initiated the project that discovered a genetic marker for response to interferon-based HCV therapy. Trained as a cellular and molecular biologist, before PharmaGenics, Art led research directed toward recombinant protein discovery and development, particularly focused on post-translational modification of peptide/protein therapeutics.
Arthur Bertelsen holds an AB from Princeton University in biochemical sciences and received his MS and PhD degrees from the program for Cellular and Molecular Biology at New York University Medical Center.
Laurent DEBUSSCHE obtained his PhD in biological chemistry at Université Pierre et Marie Curie and Institut National Agronomique Paris-Grignon. His work on Vitamin B12 biosynthesis pathway eluciadtion was recognized by Doisteau-Blustet French National Academy of Sciences in 1992. Located in Vitry Research site, he has close to 30 years experience in pharmaceutical industry. Since 1987, he has been involved in several research projects in oncology. He is Research Director at Sanofi, joined the management team of Oncology Research Department in 1998, has an extensive experience in industrial and academic project direction at national and international level, as well as in external opportunity evaluation. He contributed to entry in clinical development of several chemical and biological entities. He is co-author of more than 60 scientific publications. He is currently leading the Sanofi Oncology Research Department in Vitry.
Patrice DENÈFLE Ph.D HDR and Associate Professor at Paris-Descartes, has pioneered the field of gene therapy, and has initiated multiple programs in Human genetics, functional genomics and Onco-pharmacogenomics at Rhône-Poulenc Rorer then Sanofi-Aventis. After 3 years as CSO and head of translational R&D at Genethon, he joined Ipsen in 2010 as Senior VP, Digital and Translational Sciences, to build and run a global platform fully integrated Medical and Scientific approaches to Precision Medicine. He founded MedBiomiX Partners SAS in 2014. He was appointed VP, Head of the Roche Institute for Research and Translational Medicine in January 2015.
Denis PATRICK received his Ph.D. from the University of Pennsylvania and has worked in large Pharma oncology organizations for 27 years, including Merck, DuPont Pharma, GSK and Pfizer. Dr. Patrick is currently Executive Director and Head of External R&D Innovation (ERDI) for the Oncology Research Unit (ORU) at Pfizer. The goal of ERDI is to search and evaluate external opportunities that are focused on areas that complement Pfizer ORU research interests including antibody drug conjugation technologies, oncogenic drivers, tumor metabolism, epigenetics, immuno-oncology, and precision medicine strategies. Recent executed agreements include Macrogenics, Seattle Genetics, Stem CentRx, Epic Sciences, BIND Therapeutics, CytomX, Philogen, and iTeos. Prior to joining Pfizer, Dr. Patrick worked at GlaxoSmithKline, initially as director of Oncology Biology followed by Director of Oncology Scientific Licensing. While at GSK, Dr. Patrick was instrumental in evaluating and executing agreements with Japan Tobacco Company for the MEK inhibitor, trametinib, recently approved for treatment of metastatic melanoma, Amplimmune’s AMP224, and research agreements with Supergen, Vernalis, Proteologics, Oxford Biotherapeutics, and Seattle Genetics. During his time as Director of Oncology Biology, Dr. Patrick lead preclinical research groups delivering numerous clinical candidates, the most advanced of which is GSK’s B-Raf inhibitor, Tafinlar (dabrafenib), also recently approved for metastatic melanoma.
Mark Pearson is currently leading the Department of New Therapeutic Concept Discovery as part of Boehringer-Ingelheim Oncology research in Vienna. The department is responsible for the discovery of new cancer targets and their implementation within the early Oncology portfolio. Previously he was associate principle scientist at AstraZeneca (England) and he worked at Novartis as Laboratory Head (Switzerland). He obtained his PhD at the Paterson Institute of Cancer Research from the University of Manchester.
Robert RADINSKY, Ph.D. is Vice President, Oncology Scientific Innovation at Janssen Research & Development, LLC. He represents the Oncology Therapeutic Area in Johnson & Johnson Innovation, Boston. In this role, he is responsible for identifying and fostering innovation in the region that supports the Oncology Therapeutic Area strategies. Prior to this role, he led Discovery Research, Oncology, for Janssen.
Robert has had a very successful oncology research career in both academics and industry. Prior to joining Janssen, he was Executive Director, Oncology Research at Amgen Inc., where he led groups at multiple research sites including Thousand Oaks, California, and Cambridge, Massachusetts. He was responsible, in part, for research and/or pharmacology for numerous active targeted therapeutic anti-cancer programs (protein, small molecule and nanotechnology modalities), culminating with multiple candidates in clinical trials and an approved drug for the treatment of colorectal carcinoma.
Before joining the industry 14 years ago, Robert earned his doctorate in Molecular Biology and Microbiology from University School of Medicine in Cleveland, Ohio and was then on the faculty at The University of Texas MD Anderson Cancer Center in Houston, first serving as an American Cancer Society Postdoctoral Research Fellow in the Department of Cell Biology, and eventually becoming a tenured Associate Professor in the Department of Cancer Biology.
Robert has published more than 135 peer-reviewed articles, holds multiple patents, and is a member of numerous societies and an Editorial Member and/or ad hoc reviewer for many scientific journals.
Steven Shak, M.D., is Chief Scientific Officer of Genomic Health, Inc, which is focused on improving the quality of treatment decisions and outcomes for cancer patients. He and his colleagues have worked together with leading global oncology clinical research groups to develop the Oncotype DX® breast cancer, colon cancer, and prostate cancer assays. He spearheaded the innovative collaboration between Genomic Health and the SEER program to enhance public insights into genomics in clinical practice. Dr. Shak has previously worked at Genentech, Inc. where he led the clinical team that gained approval of trastuzumab (Herceptin®). In addition, Dr. Shak discovered, cloned, and expressed the therapeutic human enzyme human DNase I or dornase alfa (Pulmozyme®), a mucus-dissolving enzyme that continues to be a global standard of care for cystic fibrosis patients. Dr. Shak previously held faculty positions in Medicine and Pharmacology at New York University School of Medicine. Dr. Shak is currently on the Board of Directors of the Cystic Fibrosis Foundation, The Children’s Cause for Cancer Advocacy, and The Multiple Myeloma Research Foundation. Dr. Shak has an undergraduate degree from Amherst College, an MD degree from New York University School of Medicine, and post-graduate training in medicine and research at Bellevue Hospital in New York City and the University of California, San Francisco.
Mike Sheehan is a Senior Director in Product Development at MedImmune (the biologics arm of AstraZeneca), having started his industrial career in GSK in the UK. He has led teams taking a multitude of new therapies from the lab through phase 1, phase 2A and phase 2B clinical studies. Over the last 20 years he has worked on small molecule drugs, monoclonal antibodies, fusion proteins, DNA vaccines and antisense DNA, across many disease areas including respiratory, inflammation and autoimmunity, neurology, cardiovascular, metabolic disease, anti-virals, and his current focus on oncology. He obtained his PhD in neuropharmacology at Charing Cross Hospital in the University of London.
Dr. Li YAN is Head Unit Physician of Oncology at GSK. His industry career started at Johnson & Johnson where he received the Philip Hoffmann’s Scientific Award, the 2nd most prestigious award at J&J, for his contributions to the development of anti-cancer monoclonal antibodies. Prior to joining GSK, Dr. Yan was the Executive Director and Head of Clinical Development of Oncology, Infectious Disease, Respiratory & Immunology, and Vaccines for Emerging Markets at Merck. He co-authored more than 70 peer-reviewed manuscripts and 5 book chapters. He is an adjunct professor at Peking University, China, and at Yonsei University, South Korea. Dr. Yan serves as the founding Managing Director of US Chinese Anti-Cancer Association (USCACA) and an advisory panel member of Chinese Society for Clinical Oncology (CSCO).